<DOC>
	<DOCNO>NCT01389856</DOCNO>
	<brief_summary>The AC-052-391-study phase 3 study investigate whether add bosentan inhale nitric oxide newborns persistent pulmonary hypertension newborn ( PPHN ) support safe therapy evaluate pharmacokinetics bosentan metabolite .</brief_summary>
	<brief_title>Persistent Pulmonary Hypertension Newborn</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Signed informed consent parent ( ) legal representative ( ) . 2 . Term near term newborn ( gestational age &gt; 34 week ) . 3 . Post natal age ≥ 12 hour &lt; 7 day . 4 . Weight birth ≥ 2,000 g. 5 . Idiopathic PPHN PPHN due parenchymal lung disease 6 . Documented diagnosis pulmonary hypertension ( PH ) confirm echocardiography . 7 . Need continue inhaled nitric oxide ( iNO ) dose &gt; 10ppm least 4 hour continuous iNO treatment . 8 . Two oxygenation index ( OI ) value ≥ 12 take least 30 minute apart , 12 hour prior randomization patient receive iNO treatment . 9 . Mechanical ventilation fraction inspire oxygen ( FiO2 ) ≥ 50 % randomization . 1 . PH associate condition PPHN . 2 . Immediate need cardiac resuscitation extracorporeal membrane oxygenation ( ECMO ) . 3 . Lethal congenital anomaly . 4 . Congenital Diaphragmatic Hernia . 5 . Significant structural cardiac anomaly . 6 . Medically significant pneumothorax . 7 . Active seizure . 8 . Expected duration mechanical ventilation le 48 hour . 9 . Mean systemic blood pressure &lt; 35 mmHg despite therapy volume infusion cardiotonic support . 10 . Hepatic failure condition alanine aminotransferase ( ALT ) value &gt; 2 x upper limit normal ( ULN ) . 11 . Renal function impairment serum creatinine &gt; 3 x ULN anuria . 12 . Known intracranial hemorrhage grade III IV . 13 . Either hemoglobin hematocrit level &lt; 75 % low limit normal ( LLN ) . 14 . Thrombocytopenia ( platelet count &lt; 50,000 cell /µL ) . 15 . Leukopenia ( WBC &lt; 2,500 cells/ µL ) . 16 . Any condition precluding use nasogastric/orogastric tube . 17 . Administration prohibit medication prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Persistent pulmonary hypertension , newborn</keyword>
	<keyword>PPHN</keyword>
</DOC>